Skip to content
Companies

Axoft

Soft-material brain implants for stable neural recording

Raised to date

$34.2M

of $34.2M offered across 1 Form D filing

Still open
$19
Investors
13
Last filed
May 7, 2026

About

Axoft is a Cambridge, Massachusetts neurotechnology company developing implantable brain-computer interfaces (iBCIs) built on bio-inspired soft materials. Its proprietary Fleuron material is reported to be up to 10,000x softer than the polyimide used in existing brain implants, which reduces tissue scarring and lead migration and improves the stability of high-resolution neural recordings over time. The company has implanted its iBCI in 11 patients globally, including first-in-human cases at The Panama Clinic, and has published findings in Nature. Axoft combines materials science, electronics and AI-driven signal decoding to target neurological conditions such as coma, paralysis, depression, movement disorders and dementia.

A bio-inspired implant material (Fleuron) orders of magnitude softer than conventional polyimide, which Axoft reports delivers 8x greater regional access, 32x more sensors per thread and over 60% less signal attenuation while improving long-term biocompatibility.

Funding

  • EquityFiled May 7, 2026Form D
    $34.2M/ $34.2M

Product

Axoft implantable brain-computer interface (iBCI)

Implantable medical device / neurotechnology

A high-density implantable neural interface built from Axoft's Fleuron material, designed to record and stimulate brain activity at high resolution over long periods with minimally invasive surgery and access to deeper brain regions.

  • Fleuron bio-inspired material up to 10,000x softer than polyimide
  • 32x more sensors per thread and 8x greater regional access than conventional iBCIs
  • Over 60% reduced signal attenuation

Built for

Clinicians and health systems treating patients with severe neurological disorders, plus neuroscience research groups

People on file